B
카이노스메드
284620KOSDAQ자연과학 및 공학 연구개발업55.8 / 100
Reference Date: 2026-06-10
Financial Score17.5 / 40
News Sentiment16.3 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR raises overvaluation concerns, ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Kainosmed is a biotech company focused on developing innovative therapies for incurable and rare diseases, generating revenue through licensing out drug candidates. The company is currently advancing Parkinson's disease treatments and HIV therapies into Phase 2 clinical trials, while also exploring oncology drug development.
Number of Employees
15people
Average Salary
73.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 62.704.0Point
PBR
7.81Industry Average 3.240.0Point
2.4x industry avg (risky)
ROE
-148.61Industry Average -32.093.5Point
4.6x industry avg (excellent)
Debt Ratio
—Industry Average 7.314.0Point
Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲109.7% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲37.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -109.3% (declining, 3yr)
Detailed News Sentiment
1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 65
- Negative카이노스메드, 10억 규모 무통자동주사기 공급계약 해지
카이노스메드는 무통자동주사기 공급 계약 해지로 인해 재무적 부담 증가와 신뢰도 하락이 예상된다.
Detailed Momentum
52-week position3.0Point
52w lower range (37%)
Current 1,087Won52-week high 1,27052-week low 977
1-month return3.0Point
1m 0% (flat)
Volume trend6.0Point
Volume surge
Detailed Disclosure
3 totalPositive 0Neutral 3Negative 0
- Neutral[기재정정]단일판매ㆍ공급계약해지2026-05-29
- Neutral단일판매ㆍ공급계약해지2026-05-29
- Neutral분기보고서 (2026.03)2026-05-15